Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs
Figure 5
Comparison of the antitumor activity of 194-A with sunitinib or sorafenib in the 4T1 orthotopic graft model. (a) At the end of study, the tumor volume in mice treated with vehicle, 50 mg/kg/day 194-A (p.o.), sunitinib (p.o.), or sorafenib (p.o.) was measured by using a caliper. The median value of tumor volume was indicated. (b) Lung metastasis was measured at the end of study by in vivo bioluminescent signals. The median value of photon emissions was indicated. Bars, median values (). (c) 194-A, sunitinib, or sorafenib treatment did not affect the body weights significantly. Lines, mean (); bars, SE.
